MindMaze formerly Relief Therapeutics
MindMaze Therapeutics is a dual-platform digital neurotherapeutics and rare-disease biopharmaceutical company, commercializing FDA-cleared, AI-driven rehabilitation products for stroke and Parkinson's patients across 100+ hospitals and 250+ clinics globally.
- Company typePublic
- Founded2012
- HeadquartersLausanne, Switzerland
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What MindMaze formerly Relief Therapeutics does
MindMaze Therapeutics is a dual-platform digital neurotherapeutics and biopharmaceutical company formed in December 2025 through the business combination of Relief Therapeutics and NeuroX Group SA, trading on SIX Swiss Exchange (MMTX) and OTCQB (RLFTF). The digital neurotherapeutics portfolio comprises FDA-cleared and CE-marked products — MindMotion GO, MindPod, Izar, Physilog, ToapRun, and the MindMotion Companion home-engagement layer — designed to deliver gamified, AI-personalized motor, cognitive, and gait rehabilitation for stroke, Parkinson's, and broader neurological conditions. The platform runs a hybrid deterministic-plus-adaptive AI architecture that ingests approximately one million behavioral data points per month across multimodal sensor streams, supported by roughly 120 patent applications covering hardware, algorithms, and clinical protocols.
The biopharmaceutical arm develops treatments for rare and serious diseases, with disclosed pipeline assets including RLF-TD011, RLF-OD032, and RLF-100. MindMaze commercializes through hospital and rehabilitation-clinic channels, with 100+ hospital deployments and 250+ clinic installations worldwide spanning anchor accounts such as Mount Sinai, Vibra Healthcare, Johns Hopkins, Shirley Ryan AbilityLab, University College London, and University of Auckland. Revenue mechanics combine hardware/software sales, recurring clinical service fees, and — most recently — CPT Category III–coded home-based digital neurotherapy sessions, a billing pathway intended to enable sustained adoption outside acute-care settings. The company was founded in 2012 by Tej Tadi in Lausanne, Switzerland, with a US headquarters opened at The Pearl in Charlotte, North Carolina in July 2026, and approximately 101-250 employees.
MindMaze formerly Relief Therapeutics firmographics
Firmographics- Name
- MindMaze formerly Relief Therapeutics
- Legal name
- MindMaze Therapeutics SA
- Website
- https://mindmazetherapeutics.com
- Company type
- Public
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- MindMaze Therapeutics is a dual-platform digital neurotherapeutics and rare-disease biopharmaceutical company, commercializing FDA-cleared, AI-driven rehabilitation products for stroke and Parkinson's patients across 100+ hospitals and 250+ clinics globally.
- Ownership category
- akta.pro rank
MindMaze formerly Relief Therapeutics industry classification
Industry- Product category
- Digital Neurotherapeutics and Rare Disease Biopharmaceuticals
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)
- akta.pro secondary industries
- Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS) (HSADAIAC), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where MindMaze formerly Relief Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Lausanne
- HQ country
- Switzerland
- HQ region
- Europe
Offices4 records
Markets served
MindMaze formerly Relief Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- Digital Neurotherapeutics Platform: Revenue from FDA-cleared and CE-marked digital neurotherapeutic solutions deployed in hospitals, rehabilitation facilities, and patient homes. The company has secured US CPT Category III reimbursement codes for home-based therapy and is pursuing European reimbursement through clinical evidence generation.
- Biopharmaceutical Portfolio: Revenue from Relief Therapeutics' drug portfolio focused on rare dermatological, metabolic, and respiratory diseases. Includes marketed products like PKU GOLIKE, diclofenac formulations, and SETOFILM/ONDISSOLVE marketed through licensing partnerships.
- Clinical Research Services: Revenue from partnerships with pharmaceutical companies using MindMaze's proprietary technology across multiple clinical trials. The company generates evidence through sponsored clinical studies.
Go-to-market motion1 record
Distribution channels5 records
Marketing channels7 records
MindMaze formerly Relief Therapeutics product offering
Product offeringCore offering
MindMaze Therapeutics sells an FDA-cleared and CE-marked AI-powered digital neurotherapeutics platform for neurological recovery, including MindPod, MindMotion GO, Izar, Physilog, ToapRun, and MindMotion Companion, sold to hospitals, rehabilitation facilities, and healthcare providers. The company also markets and develops a portfolio of biopharmaceutical products for rare dermatological, metabolic, and respiratory diseases inherited from Relief Therapeutics.
Product overview
MindMaze Therapeutics operates as a dual-engine platform combining digital neurotherapeutics with biopharmaceutical products. The core MindMaze neurotherapeutics platform provides precision motor and cognitive assessments and treatments through an integrated ecosystem of products: MindMotion GO (game-based neurorehabilitation for clinical and home use), MindPod (immersive neuro-animation platform), Izar (smart hand peripheral), Physilog (motion analytics), ToapRun (Parkinson's gait therapy), and MindMotion Companion (monitoring and telehealth platform). The platform is enhanced by R&D initiatives including CogniChip (digital twin), MindDrive (motorsport neurotechnology), and MindSense (biometric decoding). Complementing the digital business, Relief Therapeutics contributes a portfolio of rare disease drugs including RLF-TD011 (epidermolysis bullosa), RLF-OD032 (phenylketonuria), RLF-100 (pulmonary indications), and commercialized products PKU GOLIKE, ACER-001, diclofenac formulations, and SETOFILM/ONDISSOLVE. The company holds FDA, CE/MDR, and EU MDR regulatory registrations with CPT Category III reimbursement for home-based therapy in the US.
Differentiator
Problem solved
Functional benefit
Brands
- MindMotion GO: First-of-its-kind neurorehabilitation platform using game-based digital therapies for patient training within inpatient and outpatient clinics as well as at home
- MindPod
- Izar
- Physilog
- ToapRun
- MindMotion Companion
- CogniChip
- MindDrive
- MindSense
Products and services
- MindPod Immersive neuro-animation platform providing high-intensity, high-dose training of motor and cognitive function through an animated gaming environment with a dolphin character, using motion-sensors and cameras to track patient movements in real time for brain recovery and learning.
- MindMotion GO First-of-its-kind neurorehabilitation system using game-based digital therapies for in-clinic, outpatient, and home settings, enabling high-dose, high-intensity training across the continuum of care for stroke and neurological patients.
- Izar First-in-kind FDA-listed and CE-marked hyper-sensitive smart controller for patients with hand motor function impairment; detects sub-newton finger and hand forces, enabling treatment in most impaired populations and training dexterity and strength through proprietary gaming content.
- Physilog 3D motion analytics solution that captures, measures, and analyzes digital biomarkers for patient-centric Digital Motion Assessments.
- ToapRun Game-based therapy for Parkinson's gait and balance developed in partnership with Institut du Cerveau in Paris.
- MindMotion Companion Patient monitoring and telehealth platform enabling therapists to track patient progress, schedule videoconferences (via Zoom), and manage home-based therapy programs for neurorehabilitation patients.
- CogniChip End-goal cognitive platform designed to simultaneously process and coordinate all sensory and physical inputs the brain experiences, combining elements to create a virtual self with applications spanning healthcare, transport, aviation, gaming, communications, and sports.
- MindDrive Next-generation safety and performance platform for motorsport monitoring driver brain activity and delivering targeted feedback to enhance focus, performance, and overall safety.
- MindSense Biometric data technology that decodes mental states such as focus, cognitive load, fatigue, and preference to provide athletes and sports organizations with neurocognitive intelligence.
- RLF-TD011 Differentiated hypotonic, acid-oxidizing solution formulated with hypochlorous acid for treatment of epidermolysis bullosa, granted Orphan Drug Designation by FDA.
- RLF-OD032 Innovative, highly concentrated liquid formulation of sapropterin dihydrochloride for oral administration for treatment of phenylketonuria, pursuing 505(b)(2) NDA pathway.
- RLF-100 (Aviptadil acetate) Proprietary, patent-protected Aviptadil formulations for intravenous and inhaled administration targeting acute respiratory distress syndromes and chronic lung diseases.
- ACER-001 Proprietary taste-masked formulation of sodium phenylbutyrate powder for urea cycle disorders, marketed as OLPRUVA in US by Zevra Therapeutics, with Relief holding exclusive rights for Europe.
- PKU GOLIKE First prolonged-release medical food for dietary management of phenylketonuria with special coating enabling more physiological absorption, marketed in US by Eton Pharmaceuticals.
- Diclofenac Formulations Portfolio of diclofenac formulations for multiple pain and inflammatory conditions including migraine, arthritis, and localized pain, out-licensed to third parties under brands including CAMBIA, Voltfast, and Diclo-ratiopharm.
- SETOFILM/ONDISSOLVE Orodispersible film formulation of ondansetron for prevention and treatment of nausea and vomiting, marketed as SETOFILM by Norgine in Europe and ONDISSOLVE by Takeda in Canada.
Quantifiable outcome
- 60% increase in additional therapy per day for stroke patients using MindMaze technology vs standard of care
- +3 more outcomes
Companies that use MindMaze formerly Relief Therapeutics
Customer profileNamed customers10 records
Segments4 records
Ideal customer profiles4 records
MindMaze formerly Relief Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability10 records
Feature10 records
MindMaze formerly Relief Therapeutics partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered minor and core.
- University of PittsburghminorMindMaze announced its precision neurotherapeutics technology is being used in a University of Pittsburgh study evaluating combination approach to post-stroke arm recovery. Study pairs cervical epidural spinal cord stimulation with intensive neurotherapy, testing whether combining stimulation with high-volume, intent-driven practice can produce lasting recovery gains beyond stimulation alone.
- SwissNeuroRehab ConsortiumcoreCHF 11.2 million Innosuisse-backed SwissNeuroRehab study evaluating 300 minutes of active training weekly across inpatient, outpatient, and home phases over 15-month follow-up period. First patients enrolled at six Swiss centers. Strategic effort to generate clinical and health-economic evidence for at-home reimbursement in European healthcare systems.
- Hospices Civils de LyoncoreREACT-AVC study at France's Hospices Civils de Lyon focused on early outpatient and home-based stroke rehabilitation, coordinated with SwissNeuroRehab study. Strategic effort for European at-home reimbursement evidence generation.
- Connect Labs by WexfordminorMindMaze established US headquarters at Connect Labs by Wexford at Charlotte's The Pearl Innovation District, a partnership between Atrium Health and Wexford Science & Technology. Space includes Patient Experience Center with complete MindPod installation. The Pearl includes other tenants like IRCAD North America, Siemens Healthineers, and Tract Bio.
- NeuroX Group SAcoreBusiness combination forming MindMaze Therapeutics combining NeuroX Group SA (successor of MindMaze with digital neurotherapeutics) and Relief Therapeutics (biopharmaceutical portfolio). Transaction valued NeuroX at 1 billion Swiss francs ($1.1 billion) and Relief at 100 million francs. Listed on SIX Swiss Exchange under ticker MMTX.
- Vibra HealthcarecoreMindMaze partnered with Vibra Healthcare, a leader in post-acute hospital patient care operating 90+ specialty hospitals in 19 states, to deploy MindMaze's digital health technology platform (MindPod and MindMotion GO) in-clinic and at-home. The partnership facilitates large-scale rollout across inpatient, post-acute, community sub-acute and home-based care environments. Results from two-year multi-site quality improvement program with 210 patients across five Vibra facilities showed 60% increase in therapy per day and significantly enhanced functional recovery.
- Mount Sinai Health SystemcoreMindMaze partnered with Mount Sinai Health System, one of the largest academic medical systems in the New York metro area, to pioneer a digital neurotherapeutic program accelerating patient access to novel digital interventions. The program delivers superior outcomes in motor and cognitive function through high-dose, high-intensity training including home-based digital neuro-care, assessment, and monitoring for acute and long-term recovery after stroke and concussion. Peer-reviewed Arbuckle et al. 2025 publication reports improved clinical outcomes and cost savings from home-based stroke rehabilitation.
- Alfa Romeo F1 Team ORLENminorMindMaze entered strategic partnership with Alfa Romeo F1 Team ORLEN to advance brain health, safety, and performance technologies. MindDrive platform monitors driver brain activity to enhance focus, performance, and safety. Partnership includes brand sponsorship on drivers' helmets and research at Miami Grand Prix. MindMaze also has research partnerships with Andretti Autosport Indycar team and previous partnerships with McLaren and Haas F1 teams.
- The University of AucklandcoreMindMaze partnered with The University of Auckland on Phase 2 ESPRESSo trial evaluating MindPod for early stroke intervention within two weeks of stroke. The trial assesses high-intensity, high-dose exploratory arm and hand movements for upper limb motor capacity recovery. University provides predictive tool for recovery outcomes validation in US.
- Johns Hopkins UniversitycoreMindMotion GO adopted by Johns Hopkins, one of the foremost academic medical centers in the US. Dr. John Krakauer, Professor of Neurology and Neuroscience at Johns Hopkins, serves as Chief Medical and Scientific Advisor to MindMaze. MindPod technology developed with Dr. Omar Ahmad and Dr. Krakauer from Kata studio at Johns Hopkins.
- Genious HealthcareminorAcquisition of Genious Healthcare added ToapRun to MindMaze's portfolio - a game-based therapy for Parkinson's gait and balance developed with Institut du Cerveau in Paris.
- MSquare HealthcareminorAcquisition of MSquare Healthcare secured foundation of MindPod therapy system for MindMaze platform.
- CHUV (Centre Hospitalier Universitaire Vaudois)minorClinical collaboration began with CHUV in Lausanne to test hospital neurorehabilitation platform for stroke. MindMotion PRO entered pre-clinical testing at CHUV. EPFL partnership formed foundation for MindMaze's origins and patent filing for Upper Limb Rehabilitation System.
Scale indicators9 records
Recent moves9 records
Expansion highlights5 records
MindMaze formerly Relief Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Hinge Health, Inc. Hinge Health is a leading digital musculoskeletal therapy platform with broader scope than MindMaze (covers MSK rather than neurological conditions specifically), but operates with a similar enterprise sales motion to employers/payors and applies digital therapeutic + coach delivery model.
- Medtronic plc: Medtronic is a global medtech incumbent with extensive neuroscience and rehabilitation portfolios, including neurostimulation and brain therapies — a broad incumbent that competes for the same hospital budgets and clinical decision-makers as MindMaze's neurotherapeutic platform.
- Stryker Corporation: Stryker's neurotechnology and surgical solutions divisions overlap with MindMaze's clinical customer base and broader rehabilitation/wearable strategy; Stefanie Scheurer (MindMaze's VP Sales Northern Europe) joined from Stryker, reflecting the talent and competitive overlap.
- Akili Interactive Labs, Inc. Akili is a digital therapeutics company with FDA-cleared products for cognitive conditions (ADHD, cognitive dysfunction) — a broader portfolio peer that pioneered the digital therapeutics regulatory and reimbursement pathway relevant to MindMaze's CPT Category III codes.
Direct peers
- Penumbra, Inc. Penumbra's REAL Immersive System is a VR-based digital neurorehabilitation platform targeting stroke and other neurological recovery — directly overlapping with MindMaze's MindPod and MindMotion GO in both indication and care-setting (clinical + home).
- Constant Therapy Health: Constant Therapy provides digital cognitive and speech therapy software for stroke and TBI recovery — a direct peer in the digital neurotherapeutics category serving the same clinician/patient base with software-based therapy delivery.
- Bionik Laboratories Corp. Bionik Laboratories develops robotic and digital neurorehabilitation technologies for stroke and other neurological conditions — directly comparable in product category and target customer (rehabilitation hospitals and clinics).
- Zevra Therapeutics, Inc. Zevra Therapeutics holds the US marketing rights for ACER-001 (sodium phenylbutyrate/Olpruva), which is the same compound for which MindMaze (via Relief Therapeutics) holds European rights — making Zevra a direct commercial peer in the rare disease biopharma side of the business.
- Saebo, Inc. Saebo manufactures neurorehabilitation products for stroke and upper-limb impairment including functional electrical stimulation devices, directly comparable to MindMaze's Izar smart peripheral for hand motor function and the broader neurorehab product suite.
Emerging players
- Neuro Rehab VR: Neuro Rehab VR develops VR-based neurorehabilitation experiences for clinical settings, targeting overlapping indications (stroke, TBI) with a similar gamified digital therapeutic approach but at an earlier commercial stage than MindMaze.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
MindMaze formerly Relief Therapeutics social profiles
Digital presenceMindMaze formerly Relief Therapeutics compliance and trust
Trust signalCompliance6 records
MindMaze formerly Relief Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
MindMaze formerly Relief Therapeutics leadership team
Management profileNumber of profiles
Profiles18 records
MindMaze formerly Relief Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries5 records
MindMaze formerly Relief Therapeutics funding detail
Funding detailFunding overview
Funding rounds7 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MindMaze formerly Relief Therapeutics M&A and investment
M&A and investmentM&A4 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MindMaze formerly Relief Therapeutics
What does MindMaze formerly Relief Therapeutics do?
MindMaze Therapeutics sells an FDA-cleared and CE-marked AI-powered digital neurotherapeutics platform for neurological recovery, including MindPod, MindMotion GO, Izar, Physilog, ToapRun, and MindMotion Companion, sold to hospitals, rehabilitation facilities, and healthcare providers. The company also markets and develops a portfolio of biopharmaceutical products for rare dermatological, metabolic, and respiratory diseases inherited from Relief Therapeutics.
Is MindMaze formerly Relief Therapeutics a public or private company?
MindMaze formerly Relief Therapeutics is a public company. It is classified as public and is currently operating.
When was MindMaze formerly Relief Therapeutics founded?
MindMaze formerly Relief Therapeutics was founded in 2012. It employs 51 to 100 people.
Where is MindMaze formerly Relief Therapeutics based?
MindMaze formerly Relief Therapeutics is headquartered in Lausanne, Switzerland, in the Europe region.
How does MindMaze formerly Relief Therapeutics make money?
Three revenue lines are on record. Digital Neurotherapeutics Platform is the primary driver. The others are biopharmaceutical Portfolio and clinical Research Services.
Who are MindMaze formerly Relief Therapeutics's main competitors?
Broad incumbents on record are Hinge Health, Inc., Medtronic plc, Stryker Corporation and Akili Interactive Labs, Inc.. Direct peers are Penumbra, Inc., Constant Therapy Health, Bionik Laboratories Corp., Zevra Therapeutics, Inc. and Saebo, Inc.. Neuro Rehab VR is listed as an emerging player.
Does MindMaze formerly Relief Therapeutics have an API?
No public API is recorded for MindMaze formerly Relief Therapeutics.
What industry is MindMaze formerly Relief Therapeutics in?
MindMaze formerly Relief Therapeutics's product category is Digital Neurotherapeutics and Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital), with a secondary code of HSADAIAC, Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS). Its NAICS code is 334510 and its SIC code is 3845.